Globus Medical (GMED) Earnings Date & Reports

Key Takeaways

• Globus Medical reported third quarter 2026 worldwide net sales of $763.7 million, down 0.7% from $769.0 million a year earlier and below the roughly $792 million consensus estimate.
• Non-GAAP (adjusted) diluted EPS came in at $1.23, slightly ahead of the $1.20 consensus and up from $1.18 in the prior-year quarter.
• GAAP net income rose 18.7% to $141.2 million, while GAAP diluted EPS increased to $1.04 from $0.88.
• Adjusted gross margin expanded to 69.5%, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin improved to 34.3% from 32.8% a year ago.
• The company lowered its full-year 2026 revenue guidance to $3.09 billion while reaffirming non-GAAP EPS guidance of $4.95 to $5.05.
• The board authorized a $500 million increase to the share repurchase program.
• For more detail on GMED's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• To discover automated trading ideas, explore Trending AI Robots.

Earnings Context and Why It Matters

Globus Medical's third quarter report lands at a pivotal moment for the musculoskeletal technology company. The business has been navigating the integration of Nevro, the spinal cord stimulation company acquired in 2025, while leaning on its core spine franchise for stability. Base business sales, which exclude Nevro products, grew 3% to $690.0 million, underscoring resilience in the company's core portfolio even as Nevro revenue declined 26% to $73.7 million. With shares having underperformed the broader market this year, investors are closely watching whether margin gains, disciplined spending, and the company's expanded buyback can offset softer top-line momentum and restore confidence in the growth story.

Reported Results

Globus Medical reported third quarter 2026 worldwide net sales of $763.7 million, a 0.7% decline from $769.0 million in the prior-year period and below the consensus estimate of roughly $792 million. U.S. net sales rose 0.5% year over year, while international net sales fell 5.7% on a reported basis and 5.0% on a constant-currency basis. Base business sales excluding Nevro grew 3.0% to $690.0 million, led by Enabling Technologies, which grew approximately 24%, and double-digit growth in trauma and neuromonitoring.

On profitability, GAAP net income increased 18.7% to $141.2 million, producing GAAP diluted EPS of $1.04, up from $0.88 a year earlier. Non-GAAP diluted EPS was $1.23, modestly ahead of the $1.20 consensus and up from $1.18 in the prior-year quarter. Adjusted gross margin reached 69.5%, an eighth straight quarter of sequential expansion, while adjusted EBITDA margin improved to 34.3%. The company also generated record quarterly free cash flow of $225 million.

Globus Medical lowered its full-year 2026 revenue guidance to $3.09 billion from a prior range of $3.18 billion to $3.22 billion, but reaffirmed full-year non-GAAP diluted EPS guidance of $4.95 to $5.05. The board separately authorized a $500 million increase to the share repurchase program.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a useful companion for investors tracking earnings movers like GMED and the broader medical device sector. Consider exploring the AI Screener to surface new opportunities aligned with your own criteria.

Market Reaction and Investor Sentiment

Sentiment around Globus Medical heading into the quarter was mixed, with shares underperforming the S&P 500 for much of 2026. The third quarter results delivered a split picture: earnings per share beat modestly and margins continued to improve, but revenue missed consensus and the company trimmed its full-year top-line outlook. The Nevro decline, driven by earlier softness in U.S. trial volumes and ongoing field sales rebuilding, remained a key overhang. Offsetting concerns, the reaffirmed EPS guidance, record free cash flow, and the expanded buyback signal management's confidence in earnings durability even as revenue growth moderates. Investors are likely to weigh the margin story against the slower top-line trajectory in the sessions ahead.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should watch whether Globus Medical can stabilize the Nevro franchise. Management has been rebuilding field sales territories and expects hiring, training, and deployment efforts to support a recovery, but trial volume trends will be an important leading indicator of future spinal cord stimulation demand.

Product launches are another area to monitor. The company cited delays in several key spine launches—including the SCRIPT implant line and related solutions—that limited second-half 2026 growth, and management expects these to become meaningful contributors in 2027. The timing and commercial traction of these launches will help determine whether U.S. Spine can reaccelerate.

Margin execution remains a bright spot. Adjusted gross margin has now expanded for eight consecutive quarters, and continued cost discipline, particularly in Nevro operating expenses, will be central to protecting profitability amid softer sales. The reaffirmed full-year non-GAAP EPS guidance of $4.95 to $5.05 suggests management expects margins and the buyback to offset the revenue shortfall.

Finally, investors should track the pace of share repurchases following the $500 million authorization increase, as well as any updates to 2027 guidance as the company provides more color on its growth trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations